2024-04-10 04:22:17 ET
Summary
- Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna.
- The ruling opens the way for a potential total win against Moderna, but uncertainties remain regarding the lawsuit and Arbutus' pipeline.
- The potential litigation payout could be significant, but the company's expensive pipeline development and cash burn rate are concerns.
...
Read the full article on Seeking Alpha
For further details see:
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains